What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's ...

Moderna secures up to $50 million to develop an Ebola vaccine.

With a market cap of $19.5 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing medicines and ...

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

Global health foundation Coalition for Epidemic Preparedness Innovations (CEPI) will invest $50 million to support ...

CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the ...

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US ...

Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

The hantavirus outbreak on the MV Hondius poses an ‘extremely low’ overall risk to the public, health officials said ...